Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Nauticus Robotics Debt Financing Update with Holder of Series C Convertible Preferred Stock
Nauticus Robotics received a waiver from a Series C Preferred Stock holder regarding a 'Triggering Event' that would have occurred if shares remained outstanding after September 30, 2026. The waiver extends the deadline to December 31, 2027, preventing a dividend rate increase to 18% and a 25% conversion premium. This provides the company with significant financial relief and additional time to address its preferred stock obligations without incurring default-related penalties.
Ensysce Biosciences filed an amendment to its Series C Non-Voting Convertible Preferred Stock certificate of designation to remove a cash redemption option. Previously, Section 6.5.3 allowed holders to redeem shares for cash if the company failed to deliver common stock upon conversion; this provision has now been eliminated.
OneMedNet Corporation is implementing a 1-for-10 reverse stock split of its common stock, effective September 29, 2026. The action is intended to bring the company into compliance with Nasdaq's minimum bid price requirement for continued listing. The split will reduce the outstanding share count from approximately 60.1 million to approximately 6.0 million shares.
PRA Group, Inc. announced a private offering of $400 million in senior notes due 2033. The company intends to use the net proceeds and available cash to repay approximately $400 million of outstanding borrowings under its North American revolving credit facility.
The PNC Financial Services Group announced it will redeem all $525 million of its outstanding Depositary Shares representing interests in its Series S Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock. The redemption is scheduled for November 2, 2026, at a price of $1,000 per Depositary Share plus any declared but unpaid dividends.
NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial, which evaluates obicetrapib in approximately 400 individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers and cognitive measures over a 52-week treatment period. This expansion into Alzheimer's follows biomarker signals observed in the company's Phase 3 BROADWAY trial.
Flash Sports & Media Holdings Wins $506K Contract from MindWave Innovations Inc.
Flash Sports & Media Holdings entered into a software development and technology services agreement with MindWave Innovations to build and operate 'FlashChain,' a dedicated blockchain network for sports media and ticketing. As consideration, the company will issue $506,000 in common stock and 20% of its FLASH TOKEN supply to MindWave. The partnership aims to authenticate digital broadcasting rights, video assets, and match-ticket inventory while preventing counterfeiting.
Alaska Air Group hosted its 2026 Investor Day in Seattle to outline the 'activation phase' of its Alaska Accelerate strategic plan following the acquisition of Hawaiian Airlines. The company announced targets for $1 billion in incremental profit by 2027 and plans to expand its network to at least 15 intercontinental destinations from Seattle by 2030. The event included the filing of a formal Investor Day presentation and multiple press releases detailing new premium products, loyalty program growth, and fleet expansion.
Ford Motor Credit Company LLC completed the issuance and sale of €750 million aggregate principal amount of 4.645% Notes due October 29, 2029. The notes were issued under the company's existing Euro Medium-Term Note program and registered under its effective S-3 registration statement.
Keros Therapeutics Licensing Deal with Takeda Pharmaceuticals U.S.A., Inc. Worth $20M
Keros Therapeutics announced it will receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The payment is part of a global license agreement that includes potential milestones exceeding $1.1 billion. Keros intends to distribute 25% of the net cash proceeds from this milestone to its stockholders.
Allarity Therapeutics has expanded its in-house medical laboratory capabilities to include proteomics and cell line research. These new capabilities will support deeper mechanism-of-action research for its lead asset, stenoparib, and allow the company to offer a broader range of research services to external partners. The expansion is expected to create cost efficiencies without impacting the company's current cash runway.
Imunon $1.2M Debt Financing with Streeterville Capital, LLC
Imunon, Inc. entered into an exchange agreement with Streeterville Capital, LLC to exchange $1.2 million of the principal amount of an existing Secured Promissory Note (A-1 Note) for 120 shares of newly designated Series B Preferred Stock. This transaction reduces the company's outstanding debt obligations under the A-1 Note by the amount exchanged, while the Series B Preferred Stock will carry an 8% annual return and a stated value of $12,000 per share.
TOP Financial Group Limited entered into amended appointment letters with its three independent non-executive directors to restructure their compensation. Effective October 1, 2026, the $20,000 annual share-based compensation component for each director will be replaced by an equivalent cash payment, bringing their total annual cash compensation to $50,000 each.
First United Corporation elected Steven R. Stuck, Shawn Bender, and Nina Beitzel to its Board of Directors, effective September 24, 2026. The new directors will serve until the 2027 annual meeting and have been appointed to various committees including Audit, Risk and Compliance, and Loan. The appointments bring expertise from the energy, industrial services, and real estate sectors to the board.
Bloomin' Brands $1.2B Debt Financing with Wells Fargo Bank, National Association
Bloomin’ Brands entered into a Fourth Amended and Restated Credit Agreement to extend the maturity of its $1.2 billion revolving credit facility to September 25, 2031. The refinancing maintains existing interest rate spreads and liquidity while adding a new consolidated senior secured net leverage ratio covenant of 3.50 to 1.00.
SurgePays received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending the deadline to March 22, 2027. Separately, Nasdaq confirmed the company has regained compliance with the minimum stockholders' equity requirement. The company intends to cure the bid price deficiency by effecting a reverse stock split if necessary.
Atossa Therapeutics announced a plan to issue one contingent value right (CVR) for each share of common stock, allowing shareholders to receive 25% of net proceeds from the potential monetization of its first qualifying FDA rare pediatric disease priority review voucher. The CVR payments are subject to an aggregate cap of $50 million and are tied to the company's (Z)-endoxifen development programs. The CVRs will be 'stapled' to the common stock and will not trade separately.
TransDigm Group $3B Debt Financing with The Bank of New York Mellon Trust Company, N.A.
TransDigm Inc. completed a private offering of $3.0 billion in 6.75% Senior Secured Notes maturing in 2035. The company intends to use the proceeds to repurchase $2.1 billion of its existing 6.75% Senior Secured Notes due 2028 via a tender offer and for general corporate purposes.
Unicycive Therapeutics appointed Meredith S. Manning as an independent director to its board, effective October 1, 2026. Ms. Manning, who previously served as Chief Commercial Officer of Soleno Therapeutics, will also serve as Chairperson of the Nominating and Corporate Governance Committee. The company also announced the resubmission of its New Drug Application for Oxylanthanum Carbonate with a new manufacturing vendor.
Soundthinking Signs $114M M&A Deal with Transom Capital Group, LLC
SoundThinking, Inc. has entered into a definitive agreement to be acquired by Transom Capital Group via a tender offer for $8.00 per share in cash plus a contingent value right (CVR) worth up to $3.00. The deal implies an upfront enterprise value of approximately $114 million, representing a 46% premium to the company's prior closing price, and will result in SoundThinking becoming a private company.
Cartesian Therapeutics announced positive 12-month retreatment data from its Phase 2 trial of Descartes-08 in patients with myasthenia gravis (MG). The data showed that patients who were retreated after symptom recurrence experienced deep and durable responses, with a mean MG-ADL score reduction of 6.6 points at 12 months and no new safety signals. Topline data from the Phase 3 AURORA trial is expected in the first quarter of 2027.
Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.
Aquestive Therapeutics appointed Richard J. Daly to its Board of Directors as a Class I director, effective October 14, 2026. Mr. Daly, a veteran life sciences executive with experience at AstraZeneca and Takeda, will receive an initial grant of 57,000 stock options as part of his non-employee director compensation package.
JELD-WEN Holding $135M Debt Financing with Commitment Parties
JELD-WEN entered into a commitment and consent letter with holders of 94.5% of its 2027 Senior Notes and 72.2% of its 2028 Term Loans to refinance and extend debt maturities to 2031. The transaction includes a $135 million new money debt financing to provide incremental liquidity and support the company's business plan. The agreement also involves exchange offers and consent solicitations to eliminate restrictive covenants and modify existing debt terms.
1 800 Flowers Com Divestiture to PlanetArt, LLC for $45M
1-800-FLOWERS.COM, Inc. has entered into a definitive agreement to sell its Personalization Businesses, including PersonalizationMall.com and Things Remembered, to PlanetArt, LLC for $45 million in cash. The divestiture is intended to sharpen the company's portfolio focus on its primary brands and strengthen its financial position for strategic growth initiatives. The parties also plan to enter into a commercial agreement allowing 1-800-FLOWERS.COM to continue offering select personalized products to its customers post-closing.
Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to a range of $410 million to $420 million, up from the previous range of $350 million to $370 million. The increase is driven by strong U.S. demand for its cancer therapies Amtagvi and Proleukin, representing approximately 60% annual growth.
Sherwin Williams $750M Debt Financing with Citibank, N.A.
Sherwin-Williams entered into a new $750 million senior unsecured 364-day term loan credit agreement with Citibank as administrative agent. The proceeds will be used to refinance an existing 2025 credit agreement and for general corporate purposes, including working capital. The agreement includes a financial covenant requiring a consolidated leverage ratio of no more than 3.75 to 1.00.
Altimmune, Inc. appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Mr. Menziuso joins from Centessa Pharmaceuticals and succeeds Gregory Weaver in the Principal Accounting Officer role, though Weaver remains the company's Chief Financial Officer.
BeyondSpring Divestiture to Biolin Investment Limited
BeyondSpring entered into a definitive agreement to sell its majority equity interest in its Chinese subsidiary, Bulin, to Biolin Investment Limited. In exchange for the equity, the investor will fund and conduct the China portion of the global Phase 3 DUBLIN-4 trial for Plinabulin, which is expected to cover approximately 50% of the total trial enrollment.
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA appealing a prior Complete Response Letter for reproxalap in dry eye disease. The company also extended its projected cash runway into 2029 and filed a formal supplemental presentation detailing the regulatory update and upcoming meeting with the FDA's Office of New Drugs.